Structure Therapeutics (GPCR) Financial Analysis & Valuation | Quarter Chart
Structure Therapeutics (GPCR)
GPCRPrice: $54.58
Fair Value: 🔒
🔒score
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 r... more
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and deliver... more
Description
Shares
| Market Cap | $3.14B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Raymond C. Stevens |
| IPO Date | 2023-02-03 | CAGR | — |
| Employees | 163 | Website | structuretx.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
GPCR chart loading...
Fundamentals
Technicals
| Enterprise Value | $1.51B | P/E Ratio | -22.74 |
| Forward P/E | -27.63 | PEG Ratio | — |
| P/S Ratio | 450854205567300211058933760 | P/B Ratio | 346895963301336154374144 |
| P/CF Ratio | -1647209855914676586545152 | P/FCF Ratio | -4887713374399745224605696 |
| EPS | $-2.4 | EPS Growth 1Y | 61.33% |
| EPS Growth 3Y | 46.96% | EPS Growth 5Y | — |
| Revenue Growth 1Y | 33.94% | Gross Margin | -0.52% |
| Operating Margin | -123.45% | Profit Margin | -100.58% |
| ROE | -0.21% | ROA | -0.22% |
| ROCE | -0.28% | Current Ratio | 20.48 |
| Quick Ratio | 20.48 | Cash Ratio | 3.77 |
| Debt/Equity | 0.01 | Interest Coverage | — |
| Altman Z Score | 42.39 | Piotroski Score | 2 |